Recurrent Acute Coronary Syndrome in Spontaneous Coronary Artery Dissection Authors: Anudeep Nakirikanti, Calla Khilnani, Omar Al Dhaybi, Umesh Gidwani, Daniella Kadian-Dodov, Daniel S Kikuchi Published: 2026 ABSTRACT AbstractBackgroundSpontaneous coronary artery dissection (SCAD) is an important cause of acute coronary syndrome (ACS) in vascular Ehlers-Danlos syndrome (vEDS).Case SummaryA 35-year-old with vEDS, found to have SCAD on coronary computed tomography angiography, was admitted with recurrent episodes of ACS. After each event, a heart team recommended medical management, eventually leading to resolution of symptoms without the need for invasive revascularization.Why Beyond the Guidelines?There are few guidelines for the management of recurrent ACS in the setting of SCAD, and clinicians are left without concrete recommendations for these high-risk clinical scenarios.DiscussionACS management in vEDS-associated SCAD is made challenging by limited evidence to guide risk stratification, and it remains difficult to identify patients who will require revascularization vs those who can be medically managed.Take-Home MessageIn the absence of evidence-based guidelines, SCAD management should be guided by a heart team approach.Key words: acute coronary syndrome, computed tomography, dissection, vascular disease Hospital Course Graph depicting high-sensitivity troponin trend after each acute coronary syndrome event. ECG findings, diagnostic, clinical assessment, and medication regimen are depicted chronologically from left to right. BID = twice daily; CCTA = coronary computed tomography angiography; ECG = electrocardiogram; Hs = high-sensitivity; IV = intravenous; NSTEMI = non-ST-segment elevation myocardial infarction; SCAD = spontaneous coronary artery dissection; STEMI = ST-segment myocardial infarction; TTE = transthoracic echocardiogram. Spontaneous coronary artery dissection (SCAD) is increasingly recognized as an important cause of acute coronary syndrome (ACS) and sudden cardiac death, particularly among individuals without traditional atherosclerotic risk factors and women. SCAD is characterized by epicardial coronary artery dissection in the absence of atherosclerosis, trauma, or iatrogenic injury. The mechanism for myocardial injury in SCAD is coronary artery obstruction by intramural hematoma stemming from rupture of the vasa vasorum or intimal tear. The pathophysiology underlying SCAD is not well characterized but is believed to be multifactorial, involving arteriopathies, genetic, and hormonal contributors in the setting of environmental stressors. Notably, it is recommended that all patients with SCAD undergo head-to-pelvis cross-sectional imaging to evaluate for extracoronary findings that may identity the underlying diagnosis or identify patients that may benefit from genetic testing.1,2 Connective tissues disorders that predispose to arteriopathies are an important risk factor for SCAD.2 Vascular Ehlers-Danlos syndrome (vEDS) is a rare inherited connective tissue disorder caused by mutations in the gene for type III procollagen (COL3A1), which leads to arterial fragility and hollow organ rupture.3 Arterial fragility may manifest as arterial aneurysm, dissection, and ultimately rupture.3 The natural history and clinical manifestations are dictated by the location and type of mutation in the COL3A1 gene.3 There are, however, few prospective investigations to guide the optimal management strategy in patients presenting with ACS in the setting of SCAD, and there are even fewer data for vEDS-SCAD. Approximately 20% to 50% of patients with SCAD present with ST-segment myocardial infarction (STEMI).4 The gold standard for SCAD diagnosis is invasive angiography, however, there is a risk of iatrogenic dissection or extension of existing dissection.2 There is growing interest in a coronary computed tomography angiography (CCTA)–first diagnostic strategy in select patients5; however, smaller, distal dissections may be missed given the lower spatial and temporal resolution compared to invasive coronary imaging modalities. Most coronary dissections will heal without intervention and medical therapy remains central to SCAD-ACS management.1,6, 7, 8 Both percutaneous revascularization and coronary bypass grafting carry a high risk of complications and routine revascularization should not be performed.7 Post-SCAD chest pain is common, occurring in one-third of patients, and can be due to recurrent SCAD, coronary spasm, as well as nonischemic mechanisms. Notably, there are no validated risk stratification tools to identify high-risk patients in whom medical management will not be sufficient. Herein, we present the case of a young man with vEDS with recurrent ACS events in the setting of SCAD. Through this case, we highlight the therapeutic dilemmas and multidisciplinary discussion required in the absence of clearly defined guidelines for ACS in vEDS-SCAD. Case Summary A 35-year-old man with vEDS (p.Gly438Asp, a missense mutation that disrupts the triple helix domain in COL3A1) complicated by right carotid dissection, prior abdominal aortic aneurysm requiring open repair with right aortoiliac artery bypass, and recent infrarenal aortic and renal artery dissection was admitted to the Mount Sinai Cardiac Care Unit. He initially presented to an outside hospital (hospital day 0) for several days of intermittent anginal chest pain. High-sensitivity troponin peaked at 1,168 ng/L, with no changes on electrocardiogram (ECG). Angiography was not performed, and he was medically managed for non–ST-segment elevation myocardial infarction (NSTEMI) with heparin and aspirin before being transferred to Mount Sinai (hospital day 1). Following transfer, computed tomography angiography of the neck, chest, abdomen, and pelvis showed no progression of his known aortic or carotid disease. Transthoracic echocardiogram (TTE) was notable for a left ventricular ejection fraction (LVEF) of 60% and no regional wall motion abnormalities (RWMAs) (Video 1A, Video 1B, Video 1C). Given his clinical stability, downtrending high-sensitivity troponin, and high suspicion for SCAD, CCTA was performed instead of diagnostic left heart catheterization. CCTA (Figure 1) demonstrated a 70% ostial left circumflex (LCx) lesion with distal patency. The proximal LCx had surrounding circumferential intramural hematoma. These imaging findings in the context of the patient's history and lack of risk factors for premature atherosclerotic coronary artery disease were concerning for type III SCAD. A heart team, involving cardiac surgery, interventional cardiology, vascular medicine, and cardiology, recommended medical management given the patient's clinical stability, preserved left ventricular function, and downtrending high-sensitivity troponin on the background of vEDS. He was initially managed with a nitroglycerin drip but transitioned to nicardipine drip because of headaches. Coronary Computed Tomography Angiography Demonstrating a 70% Proximal Left Circumflex Lesion (Red Arrows in (A) to (D) With Distal Patency (A) Curved multiplanar reconstruction. (B) Maximum intensity projection. (C) Volume rendering. (D) Linear multiplanar reconstruction with axial cross-section. The proximal left circumflex artery has surrounding circumferential intramural hematoma concerning for type III spontaneous coronary artery dissection. The patient subsequently (hospital day 1) (Figure 2) had an acute episode of anginal chest pain at rest with blood pressure 151/93 mm Hg and heart rate 70 beats/min. ECG was notable for new ST-segment elevations in the anterolateral leads. High-sensitivity troponin peaked at 3,005 ng/L before downtrending. Repeat TTE (Video 2A, Video 2B, Video 2C) showed no RWMA and an LVEF of 60%. The differential for his ACS was thought to be secondary to SCAD progression versus coronary vasospasm. Given the lack of RWMA on TTE, downtrending troponins, and improvement in chest pain with higher doses of nicardipine, the heart team recommended medical management in favor of an invasive strategy for STEMI. The consensus was that the risk for iatrogenic dissection with invasive angiography with or without coronary intervention in this patient with genetically proven vEDS and prior arteriopathy outweighed any potential diagnostic or therapeutic benefits after an ACS event that was hemodynamically tolerated, presented with quickly downtrending biomarkers as well as resolution of ECG findings, and led to no systolic dysfunction. Over the next several days, he was weaned off of the nicardipine drip, and his blood pressure regimen was up-titrated to metoprolol succinate 100 mg, doxazosin 4 mg, amlodipine 5 mg, and losartan 100 mg for a goal systolic blood pressure of <130 mm Hg and goal heart rate of <80 beats/min. Alpha and beta antagonists were selected, as there is an association between Ehlers-Danlos and hyperadrenergic dysautonomia. Electrocardiograms From ACS on Hospital Day 1 (A) Baseline ECG performed before hospitalization. (B) ECG performed on hospital day 1 demonstrating ST-segment elevations in the anterolateral leads. High-sensitivity troponin peaked at 3,005 ng/L. (C) ECG following nitroglycerin. ECG = electrocardiogram. The patient subsequently (hospital day 4) had another episode of anginal chest pain after working with physical therapy (blood pressure: 142/67 mm Hg and heart rate: 73 beats/min), with recurrent ST-segment elevations in the anterolateral leads (Figure 3). High-sensitivity troponin peaked at 5,311 ng/L before downtrending. Repeat TTE (Video 3A, Video 3B, Video 3C) showed no RWMA and an LVEF of 60%. Given clinical stability and high risk for any intervention, preserved left ventricular function, and downtrending troponins, the heart team again recommended intensification of medical management, as his blood pressure was elevated at the time of the event. A long-acting nitrate was added for antianginal effects, and his blood pressure regimen was up-titrated to amlodipine 10 mg, doxazosin 4 mg, metoprolol succinate 100 mg twice daily, lisinopril 20 mg twice daily, and isosorbide mononitrate 30 mg. Electrocardiograms From ACS on Hospital Day 4 (A) ECG performed on hospital day 4 demonstrating marked ST-segment elevations in the anterolateral leads. High-sensitivity troponin peaked at 5,311 ng/L. (B) ECG following nitroglycerin. ECG = electrocardiogram. Over the next several days, the patient remained asymptomatic. Despite aggressive blood pressure and heart rate control, however, he had another episode of angina (hospital day 7) (Figure 4). Blood pressure was 109/51 mm Hg and heart rate 50 beats/min. ECG was notable for worsening T-wave inversions in the anterior leads (Figure 4). High-sensitivity troponin peaked at 13,473 ng/L. Electrogardiograms From ACS on Hospital Day 7 (A) Limited ECG performed on hospital day 7 demonstrating worsening T-wave inversion in the anterior leads. Limb leads not captured. High-sensitivity troponin peaked at 13,473 ng/L. (B) ECG following nitroglycerin showing improvement in T-wave inversions. ECG = electrocardiogram. Why Beyond the Guidelines? The management of ACS due to SCAD are not included in the 2025 American College of Cardiology/American Heart Association (ACC/AHA) guideline for the management of patients with acute coronary syndrome9 and are instead covered in the 2021 ACC/AHA guideline for coronary artery revascularization7 and 2 scientific statements released by the AHA.1,6 Within these documents, however, there is little guidance for the management of recurrent ACS due to SCAD and no specific recommendations for SCAD in patients with vEDS. Case Outcome and Follow-Up After the last episode of angina, TTE (Video 4A, Video 4B, Video 4C) again showed no RWMA and an LVEF of 60%. Given the last episode occurred with well-controlled heart rate and blood pressure, improvement in symptoms with nitrate, and no evidence of left ventricular dysfunction on TTE, there was now higher concern for coronary vasospasm, and beta-blocker was discontinued. His blood pressure regimen was up-optimized for coronary vasospasm (ivabradine 7.5 mg twice daily, nifedipine 60 mg, isosorbide mononitrate 60 mg daily, guanfacine 1 mg, and doxazosin 4 mg daily). Subsequent ECG (Figure 5) and TTE (Video 5A, Video 5B, Video 5C) remained stable without evidence of ischemia. He had no further episodes of chest pain, and he was discharged with close follow-up. Eight months after discharge, he has not required hospitalization and remains symptom free. Electrocardiogram on Discharge Demonstrating Resolution of ST-Segment Abnormalities Discussion In this case, our patient with vEDS presented with NSTEMI and CCTA findings consistent with SCAD of the LCx leading to 70% occlusion. His course was complicated by 3 additional ACS events, possibly secondary to coronary vasospasm, each of which prompted a heart team discussion to consider revascularization. While uncommon, coronary vasospasm has been reported in patients with SCAD.10 Intracoronary vasodilator challenge was considered to confirm the diagnosis of coronary vasospasm; however, was deferred, as it was felt the risks of invasive coronary testing outweighed the potential diagnostic benefits. Ultimately, our patient's medication regimen was empirically optimized to manage coronary vasospasm (Figure 1), with subsequent improvement in his symptoms and no further ACS episodes. This case highlights the difficulty of managing ACS in SCAD and the importance of distinguishing between chest pain etiologies in patients with SCAD. To date, there have been no randomized controlled trials comparing medical management to invasive revascularization in SCAD-ACS, and management is largely guided by observational data and expert consensus. Observational studies have consistently found that percutaneous coronary intervention is associated with suboptimal procedural success rates and high rates of complications, including iatrogenic dissection, extension of the dissection, and hematoma propagation.2,7 The 2021 ACC/AHA/Society for Cardiovascular Angiography and Interventions guidelines for coronary artery revascularization gives a Class 2B recommendation for revascularization in patients with SCAD who have ongoing ischemia or hemodynamic instability.7 Other indications to consider revascularization include high-risk anatomy (left main disease).2,7 Although these recommendations are not specific to vEDS-SCAD, and it is not clear if management should differ for various underlying etiologies of SCAD, they provide important principles to guide heart team discussions. In patients with vEDS, invasive procedures should generally be avoided unless absolutely necessary, given the increased risk associated with the fragile connective tissue. In our case, after each ACS event the heart team recommended continued medical management; however, after each successive event the decision for medical management became more difficult given the concern for ongoing ischemia. Ultimately, it was felt the risk of intervention outweighed the potential benefits in this case given the known diagnosis of vEDS, preserved systolic function, and clinical stability. Although available guidance for SCAD strongly emphasizes medical management,1,6,7 there are little data to guide optimal medical management. There are no specific recommendations for beta-blockers, angiotensin-converting enzymes inhibitors, or angiotensin receptor blockers outside of their indications in ACS complicated by left ventricular systolic dysfunction.6 It is not known which, if any, agents promote SCAD healing. Our case demonstrates that medical management should be tailored to the underlying etiology and may require multiple iterations with aggressive up-titration. Conclusions The management of ACS secondary to SCAD is challenging, as there are a lack of large, prospective investigations to guide risk-stratification and management strategies. Moreover, it is remains unknown if management of ACS in vEDS-SCAD should differ from SCAD arising in other clinical contexts. Therefore, given the paucity of guidelines, ACS in patients with vEDS-SCAD currently relies heavily on expert consensus and should involve a heart team approach. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Take-Home Message •There are limited data to guide risk stratification, and the optimal management strategy (medical vs invasive) for ACS in patients with SCAD remains uncertain. It is clear however, that invasive strategies, including percutaneous coronary intervention and coronary artery bypass grafting, carry a high risk of complication and should be reserved for select cases following a heart team approach. There are limited data to guide risk stratification, and the optimal management strategy (medical vs invasive) for ACS in patients with SCAD remains uncertain. It is clear however, that invasive strategies, including percutaneous coronary intervention and coronary artery bypass grafting, carry a high risk of complication and should be reserved for select cases following a heart team approach. Appendix For supplemental videos, please see the online version of this paper. Appendix Video 1A Transthoracic Echocardiogram on Admission: Apical 4-Chamber View With Contrast Video 1B Transthoracic Echocardiogram on Admission: Apical 2-Chamber View With Contrast Video 1C Transthoracic Echocardiogram on Admission: Apical 3-Chamber View With Contrast Video 2A Transthoracic Echocardiogram on Hospital Day 1: Apical 4-Chamber View With Contrast Video 2B Transthoracic Echocardiogram on Hospital Day 1: Apical 2-Chamber View With Contrast Video 2C Transthoracic Echocardiogram on Hospital Day 1: Apical 3-Chamber View With Contrast Video 3A Transthoracic Echocardiogram on Hospital Day 4: Apical 4-Chamber View With Contrast Video 3B Transthoracic Echocardiogram on Hospital Day 4: Apical 2-Chamber View With Contrast Video 3C Transthoracic Echocardiogram on Hospital Day 4: Apical 3-Chamber View With Contrast. Video 4A Transthoracic Echocardiogram on Hospital Day 7: Apical 4-Chamber View With Contrast Video 4B Transthoracic echocardiogram on Hospital Day 7: Apical 2-Chamber View With Contrast Video 4C Transthoracic Echocardiogram on Hospital Day 7: Apical 3-Chamber View With Contrast Video 5A Transthoracic Echocardiogram on Discharge: Apical 4-Chamber View With Contrast Video 5B Transthoracic Echocardiogram on Discharge: Apical 2-Chamber View With Contrast Video 5C Transthoracic Echocardiogram on Discharge: Apical 3-Chamber View With Contrast References Associated Data Supplementary Materials Video 1A Transthoracic Echocardiogram on Admission: Apical 4-Chamber View With Contrast Video 1B Transthoracic Echocardiogram on Admission: Apical 2-Chamber View With Contrast Video 1C Transthoracic Echocardiogram on Admission: Apical 3-Chamber View With Contrast Video 2A Transthoracic Echocardiogram on Hospital Day 1: Apical 4-Chamber View With Contrast Video 2B Transthoracic Echocardiogram on Hospital Day 1: Apical 2-Chamber View With Contrast Video 2C Transthoracic Echocardiogram on Hospital Day 1: Apical 3-Chamber View With Contrast Video 3A Transthoracic Echocardiogram on Hospital Day 4: Apical 4-Chamber View With Contrast Video 3B Transthoracic Echocardiogram on Hospital Day 4: Apical 2-Chamber View With Contrast Video 3C Transthoracic Echocardiogram on Hospital Day 4: Apical 3-Chamber View With Contrast. Video 4A Transthoracic Echocardiogram on Hospital Day 7: Apical 4-Chamber View With Contrast Video 4B Transthoracic echocardiogram on Hospital Day 7: Apical 2-Chamber View With Contrast Video 4C Transthoracic Echocardiogram on Hospital Day 7: Apical 3-Chamber View With Contrast Video 5A Transthoracic Echocardiogram on Discharge: Apical 4-Chamber View With Contrast Video 5B Transthoracic Echocardiogram on Discharge: Apical 2-Chamber View With Contrast Video 5C Transthoracic Echocardiogram on Discharge: Apical 3-Chamber View With Contrast